Back to News
Market Impact: 0.15
60 Degrees Pharmaceuticals, Inc. Outlines Tafenoquine Clinical Program for Babesiosis and Potential sNDA in 2027
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
60 Degrees Pharmaceuticals updated its investor presentation on October 23, 2026, outlining tafenoquine’s clinical development for human babesiosis. The company is planning for a potential supplemental New Drug Application (sNDA) in 2027; the excerpt also says it submitted a statement of interest but cuts off before specifying its full purpose.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
SXTP0.30
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- Boeing 777 freighter output halted for two months over supplier row
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas